Cargando…
624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation
BACKGROUND: Fecal microbiota transplantation (FMT) can be an effective treatment of recurrent Clostridium difficile infection (CDI), although non-responsiveness to treatment remains poorly understood. Here we examine the bacterial composition of stool from FMT recipients using culture-independent me...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255550/ http://dx.doi.org/10.1093/ofid/ofy210.631 |
_version_ | 1783373967687417856 |
---|---|
author | Bogdanovich, Tatiana Morris, Alison Fitch, Adam Li, Kelvin Nettles, Rachel Sluis-Cremer, Nicolas Methe, Barbara |
author_facet | Bogdanovich, Tatiana Morris, Alison Fitch, Adam Li, Kelvin Nettles, Rachel Sluis-Cremer, Nicolas Methe, Barbara |
author_sort | Bogdanovich, Tatiana |
collection | PubMed |
description | BACKGROUND: Fecal microbiota transplantation (FMT) can be an effective treatment of recurrent Clostridium difficile infection (CDI), although non-responsiveness to treatment remains poorly understood. Here we examine the bacterial composition of stool from FMT recipients using culture-independent methods to identify associations between bacterial community structure, route of FMT administration (colonoscopy or freeze-dried encapsulated FMT (capsules)), treatment outcome and donor. We hypothesized that multiple community structures could be associated with and may better define treatment outcome. METHODS: We tested this hypothesis by analyzing bacterial composition profiles and their relationship with treatment route, outcome and donor using bioinformatics and multivariate statistics on 16S rRNA gene sequences (16S) from 21 individuals (seven male, 14 female, median 68 years) with recurrent CDI prior to and after FMT. Successful endpoint was defined as no relapse of C. difficile associated diarrhea during 12 weeks post-FMT. There were 17 successes (four colonoscopy, 13 capsules) and four failures (all capsules). Analyses of 16S profiles included permutational analysis of variance (PERMANOVA) and linear regression models applied to bacterial abundances and diversity (as responses). RESULTS: Significant differences were determined between pre- and post-FMT successes and failures (P < 1e(−4), R(2) = 0.24). No differences were seen between route (P = 0.15) or donor (P = 0.20). Profiles of failed FMT recipients were more similar to pre-FMT profiles by multidimensional scaling. Analyses of changes in abundance of pre-FMT profiles vs. outcome, controlled for age and sex, identified significant (P < 0.01) differences across 19 of the 25 most abundant taxa. Of the five most abundant taxa, Enterobacteriaceae and Esherichia-Shigella decreased significantly in successful outcomes, while Faecalibacterium, Blautia, and Bacteroides increased. However, variation in individual composition was also significant suggesting that multiple profiles represent successful outcomes. CONCLUSION: Increases in microbiota diversity are generally achieved in successful FMT regardless of administration route, although more than one bacterial composition profile can be identified. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6255550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62555502018-11-28 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation Bogdanovich, Tatiana Morris, Alison Fitch, Adam Li, Kelvin Nettles, Rachel Sluis-Cremer, Nicolas Methe, Barbara Open Forum Infect Dis Abstracts BACKGROUND: Fecal microbiota transplantation (FMT) can be an effective treatment of recurrent Clostridium difficile infection (CDI), although non-responsiveness to treatment remains poorly understood. Here we examine the bacterial composition of stool from FMT recipients using culture-independent methods to identify associations between bacterial community structure, route of FMT administration (colonoscopy or freeze-dried encapsulated FMT (capsules)), treatment outcome and donor. We hypothesized that multiple community structures could be associated with and may better define treatment outcome. METHODS: We tested this hypothesis by analyzing bacterial composition profiles and their relationship with treatment route, outcome and donor using bioinformatics and multivariate statistics on 16S rRNA gene sequences (16S) from 21 individuals (seven male, 14 female, median 68 years) with recurrent CDI prior to and after FMT. Successful endpoint was defined as no relapse of C. difficile associated diarrhea during 12 weeks post-FMT. There were 17 successes (four colonoscopy, 13 capsules) and four failures (all capsules). Analyses of 16S profiles included permutational analysis of variance (PERMANOVA) and linear regression models applied to bacterial abundances and diversity (as responses). RESULTS: Significant differences were determined between pre- and post-FMT successes and failures (P < 1e(−4), R(2) = 0.24). No differences were seen between route (P = 0.15) or donor (P = 0.20). Profiles of failed FMT recipients were more similar to pre-FMT profiles by multidimensional scaling. Analyses of changes in abundance of pre-FMT profiles vs. outcome, controlled for age and sex, identified significant (P < 0.01) differences across 19 of the 25 most abundant taxa. Of the five most abundant taxa, Enterobacteriaceae and Esherichia-Shigella decreased significantly in successful outcomes, while Faecalibacterium, Blautia, and Bacteroides increased. However, variation in individual composition was also significant suggesting that multiple profiles represent successful outcomes. CONCLUSION: Increases in microbiota diversity are generally achieved in successful FMT regardless of administration route, although more than one bacterial composition profile can be identified. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6255550/ http://dx.doi.org/10.1093/ofid/ofy210.631 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Bogdanovich, Tatiana Morris, Alison Fitch, Adam Li, Kelvin Nettles, Rachel Sluis-Cremer, Nicolas Methe, Barbara 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation |
title | 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation |
title_full | 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation |
title_fullStr | 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation |
title_full_unstemmed | 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation |
title_short | 624. Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation |
title_sort | 624. microbiota and associations with treatment outcome in fecal microbiota transplantation |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255550/ http://dx.doi.org/10.1093/ofid/ofy210.631 |
work_keys_str_mv | AT bogdanovichtatiana 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation AT morrisalison 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation AT fitchadam 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation AT likelvin 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation AT nettlesrachel 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation AT sluiscremernicolas 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation AT methebarbara 624microbiotaandassociationswithtreatmentoutcomeinfecalmicrobiotatransplantation |